Table 5.
Predictive accuracy of plasma pTau181 and total tau for elevated Aβ PET
| All (CU+MCI+AD) (N=269) | All Non-demented (CU+MCI)(N=229) | CU only (N=172) | MCI only (N=57) | |
|---|---|---|---|---|
| AUCROC (95% CI) | AUCROC (95% CI) | AUCROC (95% CI) | AUCROC (95% CI) | |
| All | ||||
| Age | 0.582 (0.514, 0.650) | 0.643 (0.572, 0.715) | 0.597 (0.512, 0.682) | 0.777 (0.653, 0.902) |
| * Age, APOE ε4− | 0.610 (0.521, 0.699) | 0.649 (0.558, 0.739) | 0.586 (0.475, 0.696) | 0.840 (0.712, 0.968) |
| * Age, APOE ε4+ | 0.614 (0.477, 0.752) | 0.681 (0.543, 0.820) | 0.670 (0.494, 0.846) | 0.720 (0.486, 0.954) |
| ≥1 APOE ε4 allele | 0.699 (0.647, 0.751) | 0.664 (0.605, 0.722) | 0.656 (0.588, 0.724) | 0.682 (0.564, 0.799) |
| Age + ≥1 APOE ε4 allele | 0.750 (0.691, 0.808) | 0.747 (0.683, 0.811) | 0.709 (0.629, 0.790) | 0.839 (0.737, 0.940) |
| Plasma Phospho-tau 181 | 0.803 (0.749, 0.856) | 0.750 (0.685, 0.814) | 0.704 (0.624, 0.785) | 0.852 (0.752, 0.952) |
| Plasma Total tau | 0.598 (0.531, 0.666) | 0.564 (0.489, 0.639) | 0.566 (0.479, 0.653) | 0.565 (0.414, 0.717) |
| * APOE ε4− | ||||
| Plasma Phospho-tau 181 | 0.737 (0.656, 0.817) | 0.691 (0.601, 0.781) | 0.653 (0.541, 0.766) | 0.772 (0.622, 0.923) |
| Plasma Total tau | 0.571 (0.479, 0.663) | 0.558 (0.460, 0.656) | 0.563 (0.450, 0.675) | 0.542 (0.329, 0.754) |
| * APOE ε4+ | ||||
| Plasma Phospho-tau 181 | 0.860 (0.761, 0.958) | 0.821 (0.705, 0.937) | 0.765 (0.608, 0.922) | 0.960 (0.871, 1.000) |
| Plasma Total tau | 0.698 (0.575, 0.821) | 0.636 (0.492, 0.779) | 0.656 (0.490, 0.823) | 0.547 (0.226, 0.868) |
Abbreviations: Aβ, amyloid-beta; APOE, apolipoprotein E; AUROC, area under the receiver operator characteristic curve; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment; PET, positron emission tomography.
*
There were 171 participants without an APOE ε4 allele; 159 were non-demented, including 122 CU and 37 MCI. There were 98 participants with an APOE ε4 allele; 70 were non-demented, including 50 CU and 20 MCI.